The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer

Gynecologic Oncology

Volumn 115, Issue 3, 2009, Pages 377-381

  Hoekstra, Anna V ^a   Hurteau, Jean A ^a   Kirschner, Carolyn V ^a   Rodriguez, Gustavo C ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Carboplatin; Paclitaxel; Recurrent ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 70350786915     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.08.021     Document Type: Article

References (43)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Rose P., Fusco N., Fluellen L., and Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16 (1998) 1494-1497
3. Dizon D., Hensley M., Poynor E., Sabbatini P., Aghajanian C., Hummer A., et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J. Clin. Oncol. 20 (2002) 1238-1247
4. Gronlund B., Hogdall C., Hansen H., and Engleholm S. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83 (2001) 128-134
5. Bookman M., Malmstrom H., Bolis G., Gordon A., Lissoni A., Krebs J., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16 (1998) 3345-3352
6. Rose P., Blessing J., Mayer A., and Homesley H. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 16 (1998) 405-410
7. Shapiro J., Millward M., Rischin D., Michael M., Walcher V., Francis P., et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63 (1996) 89-93
8. Friedlander M., Millward M., Bell D., Bugat R., Harnett P., Moreno J., et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oncol. 9 (1998) 1343-1345
9. Gordon A., Granai C., Rose P., Hainsworth J., Lopez A., Weissman C., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. 18 (2000) 3093-3100
10. Robinson J., Singh D., Bodurka-Bevers D., Wharton J., Gershenson D., and Wolf J. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol. Oncol. 82 (2001) 550-558
11. Rose P., Smrekar M., and Fusco N. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecol. Oncol. 96 (2005) 296-300
12. Vergote I., Rustin G., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]: Gynecologic Cancer Intergroup. J. Natl. Cancer Inst. 92 (2000) 1534-1535
13. Williams C., Mead G., Macbeth F., Thompson J., Whitehouse J., MacDonald H., et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J. Clin. Oncol. 3 (1985) 1455-1462
14. Neigt J., et Bokkel Huinink W., van der Berg M., van Oosterom A., Vriesendorp R., Kooyman C., et al. Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 2 (1984) 594-600
15. Omura G., Blessing J., Ehrlich C., Miller A., Yordan E., Creasman W., et al. A randomized trial of cyclophophamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 57 (1986) 1725-1730
16. McGuire W., Hoskins W., Brady M., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
17. Piccart M., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92 (2000) 699-708
18. Muggia F., Braly P., Brady M., Sutton G., Niemann T., Lentz S., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 18 (2000) 2349-2351
19. Ozols R., Bundy B., Greer B., Fowler J., Clarke-Pearson D., Burger R., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
20. Dunton C. Phase II study of weekly paclitaxel and weekly carboplatinum in recurrent ovarian and peritoneal cancer. Gynecol. Oncol. 467a (2003) 22
21. Watanabe Y., Nakai H., Ueda H., and Hoshiai H. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer. Gynecol. Oncol. 96 (2005) 323-329
22. Havrilesky L., Alvarez A., Sayer R., Lancaster J., Soper J., Berchuck A., et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol. Oncol. 88 (2003) 51-57
23. Markman M. Weekly paclitaxel in the management of ovarian cancer. Semin. Oncol. 27 (2000) 37-40
24. Anderson H., Bowman K., Ridderheim M., Rosenberg P., Sorbe B., Puistola U., et al. Sahlgrenska Hospital, Gothenburg, Sweden. Proc ASCO 38a (2000) 19
25. Yu D., Dahl G., Shames R., and Fisher P. Weekly dosing of carboplatin increases risk of allergy in children. J. Pediatr. Hematol. Oncol. 23 (2001) 349-352
26. Leiser A., Maluf F., Chi D., Sabbatini P., Hensley M., Schwartz L., et al. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. Int. J. Gynecol. Cancer 17 (2007) 379-386
27. Sehouli J., Stengel D., Mustea A., Camara O., Keil E., and Elling D. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother. Pharmacol. 61 (2008) 243-250
28. Havrilesky L., Broadwater G., Davis D., Nolte K., Barnett J., Myers E., et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol. Oncol. 113 2 (2009) 216-220
29. Moufarij M.A., Phillips D.R., and Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol. Pharmacol. 63 4 (2003) 862-869
30. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., and Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22 4 Suppl. 11 (1995) 72-79
31. van Moorsel C.J., Pinedo H.M., Veerman G., Bergman A.M., Kuiper C.M., Vermorken J.B., et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer 80 7 (1999) 981-990
32. Rose P.G., Mossbruger K., Fusco N., Smrekar M., Eaton S., and Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol. Oncol. 88 1 (2003) 17-21
33. Tewari D., Monk B.J., Hunter M., Falkner C.A., and Burger R.A. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest. New Drugs 22 4 (2004) 475-480
34. Villella J., Marchetti D., Odunsi K., Rodabaugh K., Driscoll D.L., and Lele S. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 95 3 (2004) 539-545
35. Brewer C.A., Blessing J.A., Nagourney R.A., Morgan M., and Hanjani P. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a Phase II Study of the Gynecologic Oncology Group. Gynecol. Oncol. 103 2 (2006) 446-450
36. Bozas G., Bamias A., Koutsoukou V., Efstathiou E., Gika D., Papadimitriou C., et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol. Oncol. (2007) 580-585
37. Gordon A., Fleagle J., Guthrie D., Parkin D., Gore M., Lacave A., et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
38. Ferrero J., Weber B., Geay J., Lepille D., Orfeuvre H., Combe M., et al. Second-line chemotherapy with pegylatal liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18 (2007) 236-238
39. Kaern J., Baekelandt M., and Trope C. A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. Eur J Gynaecol Oncol 23 (2002) 383-389
40. Thigpen J., Blessing J., Ball H., Hummel S., and Barrett R. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12 (1994) 1748-1753
41. Markman M., Hall J., Spitz D., Weiner S., Carson L., Van Le L., et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20 (2002) 2365-2369
42. du Bois A., Luck H., Pfisterer J., Schroeder W., Blohmer J., Kimmig R., et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol 12 (2001) 1115-1120
43. Parmar M., Ledermann J., Colombo N., du Bois A., Delaloye J., Kristensen G., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106